Seeking an optimal eradication therapy for Helicobacter pylori infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 1, 2012, Pages 7-9

  Miura, Soichiro ^a   Hokari, Ryota ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; CYTOCHROME P450 2C11; FURAZOLIDONE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RIFABUTIN;

ANTIBIOTIC RESISTANCE; ASIA; BIOTRANSFORMATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; ERADICATION THERAPY; HELICOBACTER INFECTION; INTENTION TO TREAT ANALYSIS; PERSISTENT INFECTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE;

EID: 84155174984     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06953.x     Document Type: Editorial

References (28)

1. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-600.
2. Asaka M, Kato M, Takahashi S etal. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
3. Malfertheiner P, Megraud F, O'Morain C etal. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
4. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007; 102: 1808-25.
5. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 2009; 7: 145-8.
6. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment. Pharmacol. Ther. 2007; 26: 343-57.
7. McMahon BJ, Hennessy TW, Bensler JM etal. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann. Intern. Med. 2003; 139: 463-9.
8. Hoshiya S, Watanabe K, Tokunaga K etal. Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J. Gastroenterol. 2000; 35: 10-14.
9. Romano M, Iovene MR, Russo MI etal. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J. Clin. Pathol. 2008; 61: 1112-15.
10. Furuta T, Shirai N, Takashima M etal. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001; 69: 158-68.
11. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 2006; 101: 1467-75.
12. Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment. Pharmacol. Ther. 2003; 18: 543-4.
13. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand. J. Gastroenterol. 2001; 36: 690-700.
14. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 2011; 34: 604-17.
15. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. 2006; 101: 488-96.
16. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 2008; 148: 923-31.
17. Greenberg ER, Anderson GL, Morgan DR etal. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-14.
18. Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14days? Helicobacter 2011; 16: 146-52.
19. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7days. Helicobacter 2011; 16: 139-45.
20. Miehlke S, Kirsch C, Schneider-Brachert W etal. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-19.
21. Furuta T, Sugimoto M, Kodaira C etal. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology 2010; 57: 134-9.
22. Kim SY, Jung SW, Kim JH etal. Effectiveness of three-times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. Br. J. Clin. Pharmacol. 2011 DOI: 10.1111/j.13652125.2011.04048X.
23. Attumi TA, Graham DY. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6weeks: A pilot study. J. Gastroenterol. Hepatol. 2012; 27: 59-61.
24. Leach AJ, Morris PS, Mathews JD; The Chronic Otitis Media Intervention Trial-One (COMIT1) group. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: a randomized controlled trial. BMC Pediatr. 2008; 8: 23.
25. Meropol SB, Chan KA, Chen Z etal. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol. Drug Saf. 2008; 17: 523-32.
26. Chung JW, Lee JH, Jung HY etal. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289-94.
27. Tanimura H, Kawano S, Kubo M etal. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J. Gastroenterol. 1998; 33: 23-6.
28. Furuta T, Sagehashi Y, Shirai N etal. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin. Gastroenterol. Hepatol. 2005; 3: 564-73.